A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
H. Chen(Roswell Park Comprehensive Cancer Center), Heather A. Wakelee(Palo Alto Institute), James R. Rigas(Dartmouth–Hitchcock Medical Center), Joel W. Neal(Stanford Medicine), L. Liu(Regeneron (United States)), Robert M. Jotte(Sarah Cannon), Calvin J. Kuo(Stratford University), Bo Gao(Regeneron (United States)), Jonathan W. Riess(University of California Davis Medical Center), Manuel Modiano(The University of Texas at San Antonio Health Science Center), A. Thomas DiCioccio(Anna Needs Neuroblastoma Answers), Natasha B. Leighl(Princess Margaret Cancer Centre), Alex A. Adjei(Cleveland Clinic), Julie R. Brahmer(Johns Hopkins University)
Cited by 26
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k